Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Richard J. Sové, Babita K. Verma, Hanwen Wang, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 11, pp. e005414-e005414
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Cancer immune escape: the role of antigen presentation machinery
Anoop Kallingal, Mateusz Olszewski, Natalia Maciejewska, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 8131-8141
Open Access | Times Cited: 63
Informing immunotherapy with multi-omics driven machine learning
Yawei Li, Wu Xin, Deyu Fang, et al.
npj Digital Medicine (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 22
Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager
Samira Anbari, Hanwen Wang, Yu Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 23
Antitumor immunostimulatory activity of the traditional Chinese medicine polysaccharide on hepatocellular carcinoma
Yang Liu, Jiawen Wu, Huiqin Hao
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 17
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities
Hengdong Qu, Junli Liu, Di Zhang, et al.
Cells (2023) Vol. 12, Iss. 15, pp. 1930-1930
Open Access | Times Cited: 16
Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery
Shuming Zhang, Atul Deshpande, Babita K. Verma, et al.
Cancer Research (2024) Vol. 84, Iss. 16, pp. 2734-2748
Closed Access | Times Cited: 7
Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology
Theinmozhi Arulraj, Hanwen Wang, Alberto Ippolito, et al.
Briefings in Bioinformatics (2024) Vol. 25, Iss. 3
Open Access | Times Cited: 6
A Scoping Review of Artificial Intelligence Applications in Clinical Trial Risk Assessment
Douglas Teodoro, Nona Naderi, Anthony Yazdani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models
Romain Désert, Fabio Gianonne, Antonio Saviano, et al.
npj gut and liver. (2025) Vol. 2, Iss. 1
Open Access
Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2358-2358
Open Access | Times Cited: 11
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Ghazaal Roozitalab, Behnaz Abedi, Saber İmani, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 889-918
Closed Access | Times Cited: 4
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy
Huiyang Liu, Yiming Lu, Jinbao Zong, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight
Anqi Li, Rui Wang, Yu-Qiang Zhao, et al.
Metabolites (2024) Vol. 14, Iss. 6, pp. 325-325
Open Access | Times Cited: 3
Cancer immunotherapy and its facilitation by nanomedicine
Chao Sui, Heqing Wu, Xinxin Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade
Theinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 45
Open Access | Times Cited: 3
Mortality Evaluation and Life Expectancy Prediction of Patients with Hepatocellular Carcinoma with Data Mining
Che-Yu Liu, Chen-Yang Cheng, Szu-Ying Yang, et al.
Healthcare (2023) Vol. 11, Iss. 6, pp. 925-925
Open Access | Times Cited: 7
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade
Theinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade glioma.
Feng Xiao, Gufeng Sun, Hong Zhu, et al.
PubMed (2023) Vol. 13, Iss. 5, pp. 2135-2154
Closed Access | Times Cited: 6
Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial
Shuming Zhang, Atul Deshpande, Babita K. Verma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence
Jianming Yang, Shijie Jiang, Yewu Chen, et al.
Current Oncology (2023) Vol. 30, Iss. 2, pp. 1708-1719
Open Access | Times Cited: 5
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges
Akihiko Goto, Yuu Moriya, Miyu Nakayama, et al.
Drug Metabolism and Pharmacokinetics (2024) Vol. 56, pp. 101003-101003
Open Access | Times Cited: 1
The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions
Ning Jia, Yutao Wang, Zijia Tao
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
Julien Edeline, Tim Meyer, Jean‐Frédéric Blanc, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5868-5868
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top